Skip to content

Study · Observational study · n = 29 · 2005

3 results

[Hepatocellular carcinoma with tumor thrombi in the portal vein. A comparison of therapeutic effects by different treatments].

Cheng SQ, Wu MC, Chen H, Shen F, Yang JH, Cong WM, Zhao YX, Wang PJ, Ding GH

Zhonghua zhong liu za zhi [Chinese journal of oncology]1 Mar 2005Cited by 8 (Europe PMC)

PMID15946574 (opens in a new tab)PepBankPUB-15946574
Publisher pageAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In patients with hepatocellular carcinoma and portal vein tumor thrombus, the rate of thrombus shrinkage or disappearance was reported as 66.7% with thymosin alpha1 and 70.0% without it, with no test given.

    In plain wordsIn patients with liver cancer and a portal vein tumor clot, clot shrinkage was 66.7% with thymosin alpha‑1 and 70.0% without. No test was reported.

    Peptide
    Thymosin alpha-1
    Outcome
    Direction not reportedPVTT shrinkage or disappearance rate
    Study

    n = 29

    Comparator
    Group B (resection, PVTT removal and TACE, no thymosin alpha1)
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated

    Measurements

    PVTT shrinkage or disappearance rate
    66.7%
    Group A
    PVTT shrinkage or disappearance rate
    70%
    Group B

    Source sentences

    Summary
    The rate of PVTT shrinkage or disappearance of groups A, B, C, D and E was 66.7%, 70.0%, 57.1%, 7.9% and 0, respectively with respective median survival time of 10.0, 7.0, 8.0, 5.0 and 2.0 months.
    1 context sentence
    Summary · context
    2003, a total of 84 HCC patients with PVTT were divided into five groups based on methed of treatment: Group A (n = 9), HCC resection + PVTT removal + postoperative TACE + thymosin alpha(1); Group B (n = 20), HCC resection + PVTT removal + postoperative TACE; Group C (n = 7), HCC resection + PVTT re…
  2. 02HumanObservational studyEfficacy outcome

    In patients with hepatocellular carcinoma and portal vein tumor thrombus, median survival was longer with postoperative thymosin alpha1 than without it, with no test given.

    In plain wordsIn patients with liver cancer and a portal vein tumor clot, survival was longer with thymosin alpha‑1 than without. No test was reported.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseMedian survival
    Study

    n = 29

    Comparator
    Group B (resection, PVTT removal and TACE, no thymosin alpha1)
    Outcome group
    Mortality · Cancer
    Studied dose
    Dose not stated

    Measurements

    Median survival
    10 months
    Group A
    Median survival
    7 months
    Group B

    Source sentences

    Summary
    The rate of PVTT shrinkage or disappearance of groups A, B, C, D and E was 66.7%, 70.0%, 57.1%, 7.9% and 0, respectively with respective median survival time of 10.0, 7.0, 8.0, 5.0 and 2.0 months.
    1 context sentence
    Summary · context
    2003, a total of 84 HCC patients with PVTT were divided into five groups based on methed of treatment: Group A (n = 9), HCC resection + PVTT removal + postoperative TACE + thymosin alpha(1); Group B (n = 20), HCC resection + PVTT removal + postoperative TACE; Group C (n = 7), HCC resection + PVTT re…
  3. 03HumanObservational studyEfficacy outcome

    In patients with hepatocellular carcinoma and portal vein tumor thrombus, the one year survival rate was higher with postoperative thymosin alpha1 than without it, with no test given.

    In plain wordsIn patients with liver cancer and a portal vein tumor clot, one-year survival was higher with thymosin alpha‑1 than without. No test was reported.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseOne-year survival rate
    Study

    n = 29

    Comparator
    Group B (resection, PVTT removal and TACE, no thymosin alpha1)
    Outcome group
    Mortality · Cancer
    Studied dose
    Dose not stated

    Measurements

    One-year survival rate
    44.4%
    Group A
    One-year survival rate
    15%
    Group B

    Source sentences

    Summary
    The one year survival rate was 44.4%, 15.0%, 14.3%, 10.5% and 0.
    1 context sentence
    Summary · context
    2003, a total of 84 HCC patients with PVTT were divided into five groups based on methed of treatment: Group A (n = 9), HCC resection + PVTT removal + postoperative TACE + thymosin alpha(1); Group B (n = 20), HCC resection + PVTT removal + postoperative TACE; Group C (n = 7), HCC resection + PVTT re…

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    12 Oct 2026, 17:28 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.